E
Elena Aurrecoechea
Researcher at University of Cantabria
Publications - 58
Citations - 857
Elena Aurrecoechea is an academic researcher from University of Cantabria. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 48 publications receiving 594 citations.
Papers
More filters
Journal ArticleDOI
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients
Javier Loricera,Ricardo Blanco,José L. Hernández,Santos Castañeda,Antonio Mera,Eva Perez-Pampin,Peiró E,A. Humbría,Jaime Calvo-Alén,Elena Aurrecoechea,Javier Narváez,A. Sanchez-Andrade,Paloma Vela,Elvira Díez,C. Mata,Pau Lluch,Concepción Moll,Íñigo Hernández,Vanesa Calvo-Río,Francisco Ortiz-Sanjuán,Carmen González-Vela,Trinitario Pina,Miguel A. González-Gay +22 more
TL;DR: TCZ therapy leads to rapid and maintained improvement in patients with refractory GCA and/or with unacceptable side effects related to corticosteroids, however, the risk of infection should be kept in mind when using this drug in Patients with GCA.
Journal ArticleDOI
Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients
Vanesa Calvo-Río,Ricardo Blanco,Emma Beltrán,Juan Sánchez-Bursón,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Marisa Hernandez Garfella,Elia Valls Pascual,Lucía Martínez-Costa,Agusti Sellas-Fernández,Miguel Cordero Coma,Manuel Díaz-Llopis,Roberto Gallego,David Salom,José Luis García Serrano,Norberto Ortego,José M. Herreras,Alejandro Fonollosa,Ángel García-Aparicio,O. Maíz,Ana Blanco,Ignacio García-De La Torre,Cruz Fernández-Espartero,Vega Jovani,Diana Peiteado-Lopez,Esperanza Pato,Juan Cruz,Carlos Marras Fernandez-Cid,Elena Aurrecoechea,M A García,M.A. Caracuel,Carlos Montilla,Antonio Atanes,Félix Francisco Hernandez,Santos Insua,Senén González-Suárez,Amalia Sánchez-Andrade,Fernando Gamero,L. Linares,Fredeswinda Romero-Bueno,A Javier García,Raquel Almodóvar,Enrique Minguez,Carmen Carrasco Cubero,Alejandro Olivé,J. Vazquez,Oscar Ruiz Moreno,Fernando Jiménez-Zorzo,Javier Manero,Santiago Muñoz Fernández,Javier Rueda-Gotor,Miguel A. González-Gay +52 more
TL;DR: Anti-TNF-α therapy is effective and relatively safe in refractory BD uveitis and the best-corrected visual acuity and the suppression load also showed significant improvement.
Journal Article
Tocilizumab in refractory aortitis: study on 16 patients and literature review.
Javier Loricera,Ricardo Blanco,Santos Castañeda,A. Humbría,Norberto Ortego-Centeno,Javier Narváez,C. Mata,Sheila Melchor,Elena Aurrecoechea,Jaime Calvo-Alén,Pau Lluch,Concepción Moll,M. Mínguez,Gabriel Herrero-Beaumont,B. Bravo,E. Rubio,Mercedes Freire,Peiró E,Carmen González-Vela,Javier Rueda-Gotor,Trinitario Pina,Natalia Palmou-Fontana,Calvo-Río,Francisco Ortiz-Sanjuán,M. A. González-Gay +24 more
TL;DR: TCZ appears to be effective and relatively safe in patients with inflammatory aortitis refractory to corticosteroids or to other biologic immunosuppressive drugs.
Journal ArticleDOI
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
N. Vegas-Revenga,Vanesa Calvo-Río,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Emma Beltrán,Elia Valls Pascual,David Díaz-Valle,Gisela Díaz-Cordovés,Marisa Hernández-Garfella,Lucía Martínez-Costa,Inmaculada Calvo,Antonio Atanes,L. Linares,Consuelo Modesto,Carmen González-Vela,R. Demetrio-Pablo,Elena Aurrecoechea,Miguel Cordero,L Domínguez-Casas,Belén Atienza-Mateo,José Luis Martín-Varillas,Javier Loricera,Natalia Palmou-Fontana,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +26 more
TL;DR: Macular thickness is reduced following administration of tocilizumab (TCZ) in refractory uveitis-related CME, a statistically significant improvement in macular thickness compared to baseline.
Journal ArticleDOI
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Monica Calderón-Goercke,Javier Loricera,Vicente Aldasoro,Santos Castañeda,Ignacio Villa,A. Humbría,Clara Moriano,Susana Romero-Yuste,Javier Narváez,Catalina Gomez-Arango,Eva Perez-Pampin,Rafael Melero,Elena Becerra-Fernández,Marcelino Revenga,Noelia Alvarez-Rivas,Carles Galisteo,Francisca Sivera,Alejandro Olivé-Marqués,María Álvarez del Buergo,Luisa Marena-Rojas,Carlos Fernández-López,Francisco Navarro,Enrique Raya,Eva Galíndez-Agirregoikoa,Beatriz Arca,Roser Solans-Laqué,Arantxa Conesa,C. Hidalgo,Carlos Vázquez,José Andrés Román-Ivorra,Pau Lluch,Sara Manrique-Arija,Paloma Vela,Eugenio de Miguel,Carmen Torres-Martín,Juan Carlos Nieto,Carmen Ordas-Calvo,Eva Salgado-Pérez,Cristina Luna-Gomez,F. Javier Toyos-Sáenz de Miera,N. Fernández-Llanio,Antonio García,Carmen Larena,Natalia Palmou-Fontana,Vanesa Calvo-Río,Diana Prieto-Peña,Carmen González-Vela,Alfonso Corrales,María Varela-García,Elena Aurrecoechea,Raquel Dos Santos,Ángel García-Manzanares,Norberto Ortego,Sabela Fernández,Francisco Ortiz-Sanjuán,Montserrat Corteguera,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +58 more
TL;DR: In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA and serious infections appear to be higher than in clinical trials.